Literature DB >> 23240731

The impact of recurrent gestational diabetes on maternal metabolic and cardiovascular risk factors.

Yvonne Winhofer1, Andrea Tura, Thomas Prikoszovich, Christine Winzer, Barbara Schneider, Giovanni Pacini, Anton Luger, Alexandra Kautzky-Willer.   

Abstract

OBJECTIVE: The development of overt diabetes in women with prior gestational diabetes mellitus (priorGDM) has been linked to several risk factors including age, obesity and insulin therapy during pregnancy; the role of recurrent GDM as a further risk factor remains unclear. As studies examining detailed metabolic consequences of recurrent GDM are missing and the role of recurrent GDM on cardiovascular risk is unknown, our aim was to investigate the impact of recurrent GDM (within 5 years after an index pregnancy) on metabolic and cardiovascular parameters.
METHODS: Oral and intravenous glucose tolerance tests as well as assessment of cardiovascular risk factors were performed at baseline (6 months after index pregnancy) and 5 years thereafter in 21 prior GDM with recurrent GDM (recGDM), 41 prior GDM with no additional pregnancy (nonrecGDM) and 10 healthy controls [CON].
RESULTS: Despite weight gain in recGDM (2·3 ± 5·1 vs. -1·3 ± 6·7 kg, P < 0·04), glucose tolerance, insulin sensitivity and secretion did not differ compared with nonrecGDM at baseline and follow-up. Furthermore, recGDM did not exhibit increased cardiovascular risk factors. Metabolic deterioration in (19% of) the total priorGDM group was associated with decreased insulin sensitivity (OGIS:367·4 ± 89·6 vs. 436·4 ± 75·5 mL/min*m², P = 0·01), hyperinsulinaemia (TIS:37·9 ± 9·7 vs. 28·0 ± 10·2 nM, P < 0·006) and postchallenge hyperglycaemia at 5 years postpartum.
CONCLUSIONS: Recurrence of gestational diabetes was not associated with deterioration of glucose metabolism, insulin sensitivity and secretion nor with increased cardiovascular risk. Consequently, priorGDM should not be recommended to refrain from subsequent pregnancies, but be encouraged to regain and maintain normal body weight after delivery and regularly undergo OGTTs to early detect metabolic deterioration.
© 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23240731     DOI: 10.1111/eci.12031

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Placental histomorphometry in gestational diabetes mellitus: the relationship between subsequent type 2 diabetes mellitus and race/ethnicity.

Authors:  Rhonda Bentley-Lewis; Deanna L Dawson; Julia B Wenger; Ravi I Thadhani; Drucilla J Roberts
Journal:  Am J Clin Pathol       Date:  2014-04       Impact factor: 2.493

2.  Factors associated with diabetes mellitus prediction among pregnant Arab subjects with gestational diabetes.

Authors:  Naji Aljohani; Amal Al Serehi; Amjad M Ahmed; Badr Aldin M Buhary; Saad Alzahrani; Eeman At-Taras; Najla Almujally; Maha Alsharqi; Mohammed Alqahtani; Mussa Almalki
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

3.  Hidden metabolic disturbances in women with normal glucose tolerance five years after gestational diabetes.

Authors:  Yvonne Winhofer; Andrea Tura; Anita Thomas; Thomas Prikoszovich; Christine Winzer; Giovanni Pacini; Anton Luger; Alexandra Kautzky-Willer
Journal:  Int J Endocrinol       Date:  2015-03-22       Impact factor: 3.257

4.  Effect of gestational diabetes and hypertensive disorders of pregnancy on postpartum cardiometabolic risk.

Authors:  Ling-Jun Li; Izzuddin M Aris; Lin Lin Su; Yap Seng Chong; Tien Yin Wong; Kok Hian Tan; Jie Jin Wang
Journal:  Endocr Connect       Date:  2018-02-14       Impact factor: 3.335

5.  Hepatic rather than cardiac steatosis relates to glucose intolerance in women with prior gestational diabetes.

Authors:  Yvonne Winhofer; Martin Krššák; Peter Wolf; Andrea Tura; Christian-Heinz Anderwald; Lana Kosi; Gert Reiter; Giovanni Pacini; Siegfried Trattnig; Anton Luger; Michael Krebs; Alexandra Kautzky-Willer
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.